| 1 | Carbapenem-resistant Enterobacterales in solid organ transplant recipients | 4.5 | 7 | Citations (PDF) |
| 2 | Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort | 3.7 | 2 | Citations (PDF) |
| 3 | Molecular epidemiology and patient outcome of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network | 1.8 | 2 | Citations (PDF) |
| 4 | How do I manage a patient with Stenotrophomonas maltophilia infection? | 5.3 | 12 | Citations (PDF) |
| 5 | Neighborhood deprivation, antimicrobial resistance, and mortality in patients with Enterobacterales: A retrospective cohort study 2025, 2, 105108 | | 1 | Citations (PDF) |
| 6 | Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19 | 5.2 | 9 | Citations (PDF) |
| 7 | Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions | 5.2 | 92 | Citations (PDF) |
| 8 | Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis | 1.4 | 2 | Citations (PDF) |
| 9 | Carbapenem-resistant Enterobacterales in Children at 18 US Health Care System Study Sites: Clinical and Molecular Epidemiology From a Prospective Multicenter Cohort Study | 0.8 | 10 | Citations (PDF) |
| 10 | Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii | 3.3 | 7 | Citations (PDF) |
| 11 | Reviewing novel treatment options for carbapenem-resistant
Enterobacterales | 3.8 | 23 | Citations (PDF) |
| 12 | Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021 | 5.2 | 5 | Citations (PDF) |
| 13 | COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina | 3.1 | 4 | Citations (PDF) |
| 14 | Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan | 3.1 | 8 | Citations (PDF) |
| 15 | Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales | 3.1 | 5 | Citations (PDF) |
| 16 | Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization | 5.2 | 0 | Citations (PDF) |
| 17 | ARGONAUT-III and -V: susceptibility of carbapenem-resistant
Klebsiella pneumoniae
and multidrug-resistant
Pseudomonas aeruginosa
to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime | 4.1 | 14 | Citations (PDF) |
| 18 | Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections | 3.1 | 4 | Citations (PDF) |
| 19 | Aetiology, susceptibility and outcomes of fever in patients receiving chemotherapy in Malawi: a prospective study | 1.8 | 1 | Citations (PDF) |
| 20 | The Prevalence of Multidrug Resistance in Enterobacterales Is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation | 0.8 | 2 | Citations (PDF) |
| 21 | Duration of antibiotic treatment for acute graft pyelonephritis: What's the standard of care? | 2.2 | 2 | Citations (PDF) |
| 22 | Impact of childhood malnutrition and intestinal microbiota on MDR infections | 1.8 | 15 | Citations (PDF) |
| 23 | Utility of Urine Cultures During Febrile Neutropenia Workup in Hematopoietic Stem Cell Transplantation Recipients Without Urinary Symptoms | 0.8 | 8 | Citations (PDF) |
| 24 | International Epidemiology of Carbapenemase-Producing Escherichia coli | 5.2 | 35 | Citations (PDF) |
| 25 | Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections | 5.2 | 558 | Citations (PDF) |
| 26 | Treatment approaches for severe Stenotrophomonas maltophilia infections | 3.3 | 29 | Citations (PDF) |
| 27 | Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant Pseudomonas aeruginosa and KPC-Producing Enterobacterales | 0.8 | 14 | Citations (PDF) |
| 28 | Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic | 4.5 | 75 | Citations (PDF) |
| 29 | Resistance in Enterobacterales Is Higher Among People Living With Human Immunodeficiency Virus | 5.2 | 12 | Citations (PDF) |
| 30 | Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study | 16.5 | 313 | Citations (PDF) |
| 31 | Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017 | 0.8 | 7 | Citations (PDF) |
| 32 | Considerations for the Use of Phage Therapy in Clinical Practice | 4.1 | 372 | Citations (PDF) |
| 33 | Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-ResistantAcinetobacter baumannii, andStenotrophomonas maltophiliaInfections | 5.2 | 476 | Citations (PDF) |
| 34 | Clinical challenges treatingStenotrophomonas maltophiliainfections: an update | 1.8 | 140 | Citations (PDF) |
| 35 | An overview of COVID-19 in solid organ transplantation | 5.3 | 17 | Citations (PDF) |
| 36 | Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX | 4.4 | 30 | Citations (PDF) |
| 37 | Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance | 4.4 | 81 | Citations (PDF) |
| 38 | Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I) | 0.8 | 46 | Citations (PDF) |
| 39 | Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) | 5.2 | 472 | Citations (PDF) |
| 40 | Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study) | 3.5 | 31 | Citations (PDF) |
| 41 | Carbapenemase-Encoding Gene Copy Number Estimator (CCNE): a Tool for Carbapenemase Gene Copy Number Estimation | 3.5 | 15 | Citations (PDF) |
| 42 | Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections | 3.9 | 120 | Citations (PDF) |
| 43 | Characteristics of community-acquired carbapenem-resistant Enterobacterales | 3.1 | 22 | Citations (PDF) |
| 44 | Antimicrobial-resistant Enterobacterales colonization in people with HIV | 1.8 | 9 | Citations (PDF) |
| 45 | Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study | 4.4 | 14 | Citations (PDF) |
| 46 | Early appropriate diagnostics and treatment of MDR Gram-negative infections | 1.8 | 54 | Citations (PDF) |
| 47 | Multidrug-Resistant Gram-Negative Bacteria in Burn Patients | 4.1 | 28 | Citations (PDF) |
| 48 | A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections | 4.1 | 11 | Citations (PDF) |
| 49 | Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV | 0.8 | 15 | Citations (PDF) |
| 50 | Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study | 0.8 | 16 | Citations (PDF) |
| 51 | Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients WithMycobacterium AbscessusInfections and Review of Literature | 0.8 | 13 | Citations (PDF) |
| 52 | Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015 | 3.7 | 34 | Citations (PDF) |
| 53 | Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections | 5.2 | 46 | Citations (PDF) |
| 54 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) | 5.2 | 428 | Citations (PDF) |
| 55 | Sulfonamides without trimethoprim in the treatment of Nocardia infections: A case report and literature review | 2.2 | 7 | Citations (PDF) |
| 56 | Antibacterial Resistance Leadership Group 2.0: Back to Business | 5.2 | 13 | Citations (PDF) |
| 57 | Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005–2015Aids, 2021, 35, 1229-1239 | 2.5 | 13 | Citations (PDF) |
| 58 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), andPseudomonas aeruginosawith Difficult-to-Treat Resistance (DTR-P. aeruginosa) | 5.2 | 294 | Citations (PDF) |
| 59 | Impact of Surgical and Medical Treatment on Survival of Patients with Cerebral Aspergillosis: Systematic Review of the Literature | 1.5 | 6 | Citations (PDF) |
| 60 | Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions | 2.6 | 134 | Citations (PDF) |
| 61 | Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients | 2.1 | 152 | Citations (PDF) |
| 62 | COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study | 4.5 | 54 | Citations (PDF) |
| 63 | Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals | 3.0 | 44 | Citations (PDF) |
| 64 | A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. | 5.3 | 21 | Citations (PDF) |
| 65 | Antimicrobial Resistance in Enterobacterales and Its Contribution to Sepsis in Sub-saharan Africa | 2.4 | 19 | Citations (PDF) |
| 66 | Genomic epidemiology of Escherichia coli isolates from a tertiary referral center in Lilongwe, Malawi | 2.0 | 21 | Citations (PDF) |
| 67 | Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years | 3.7 | 5 | Citations (PDF) |
| 68 | The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections | 5.2 | 98 | Citations (PDF) |
| 69 | Polymyxin Resistance in Klebsiella pneumoniae: Complexity at Every Level | 5.2 | 12 | Citations (PDF) |
| 70 | Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections | 5.2 | 6 | Citations (PDF) |
| 71 | Multidrug-Resistant Bacteria in the Community | 3.1 | 179 | Citations (PDF) |
| 72 | Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK | 1.5 | 2 | Citations (PDF) |
| 73 | The impact of the COVID-19 pandemic on antimicrobial resistance: a debate | 1.8 | 33 | Citations (PDF) |
| 74 | A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli | 5.6 | 34 | Citations (PDF) |
| 75 | Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study | 16.5 | 311 | Citations (PDF) |
| 76 | Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia | 5.3 | 59 | Citations (PDF) |
| 77 | ARGONAUT II Study of the
In Vitro
Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae | 4.1 | 16 | Citations (PDF) |
| 78 | Innovative strategies to fight antimicrobial resistance: crowdsourcing to expand medical training | 0.5 | 4 | Citations (PDF) |
| 79 | Preventing infectious complications when treating non‐malignant immune‐mediated hematologic disorders | 6.5 | 27 | Citations (PDF) |
| 80 | Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC | 4.1 | 53 | Citations (PDF) |
| 81 | Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria | 0.5 | 35 | Citations (PDF) |
| 82 | 622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS) | 0.8 | 0 | Citations (PDF) |
| 83 | 2276. Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study | 0.8 | 1 | Citations (PDF) |
| 84 | 625. Genomic Epidemiology of Carbapenem-Resistant Enterobacteriaceae from Colombia: A Prospective Multicenter Study | 0.8 | 2 | Citations (PDF) |
| 85 | 730. Cefiderocol for the Treatment of Achromobacter xylosoxidans Infections in Two Lung Transplant Patients with Cystic Fibrosis | 0.8 | 3 | Citations (PDF) |
| 86 | 636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States | 0.8 | 2 | Citations (PDF) |
| 87 | Carbapenemase-producing organisms in solid organ transplantation | 1.7 | 6 | Citations (PDF) |
| 88 | The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae | 0.8 | 18 | Citations (PDF) |
| 89 | Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS) | 5.2 | 12 | Citations (PDF) |
| 90 | ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Enterobacteriaceae
with Defined Extended-Spectrum β-Lactamases and Carbapenemases | 4.1 | 101 | Citations (PDF) |
| 91 | Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria | 0.5 | 23 | Citations (PDF) |
| 92 | Respiratory Viral Infections in Lung Transplant Recipients: Implications for Long Term Outcomes and Emerging Therapies | 0.1 | 3 | Citations (PDF) |
| 93 | Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae | 5.2 | 626 | Citations (PDF) |
| 94 | Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae | 4.1 | 94 | Citations (PDF) |
| 95 | Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins | 1.6 | 15 | Citations (PDF) |
| 96 | Burn injury outcomes in patients with pre-existing diabetic mellitus: Risk of hospital-acquired infections and inpatient mortality | 2.2 | 18 | Citations (PDF) |
| 97 | 1039. Surveillance Blood Cultures Associated With Decreased Mortality in Gram-Negative Bacteremia | 0.8 | 0 | Citations (PDF) |
| 98 | 470 Trends in Pediatric Inpatient Burns: A Single Center Study | 0.9 | 0 | Citations (PDF) |
| 99 | China–United States Research Collaborations in Antimicrobial Resistance | 5.2 | 5 | Citations (PDF) |
| 100 | Reply to Elamin et al | 5.2 | 1 | Citations (PDF) |
| 101 | Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae | 0.8 | 13 | Citations (PDF) |
| 102 | Endemic Mycoses in Solid Organ Transplant Recipients | 3.1 | 27 | Citations (PDF) |
| 103 | Combined Medical and Surgical Management of Hepatic Mucormycosis in an Adult with Acute Myeloid Leukemia: Case Report and Review of the Literature | 2.4 | 5 | Citations (PDF) |
| 104 | Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality | 5.2 | 209 | Citations (PDF) |
| 105 | Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? | 4.1 | 282 | Citations (PDF) |
| 106 | Improved Survival of Patients With Extensive Burns | 0.9 | 45 | Citations (PDF) |
| 107 | NDM-5 and OXA-181 Beta-Lactamases, a Significant Threat Continues To Spread in the Americas | 4.1 | 78 | Citations (PDF) |
| 108 | Life-threatening Skin Disorders Treated in the Burn Center | 1.8 | 7 | Citations (PDF) |
| 109 | Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group | 5.2 | 126 | Citations (PDF) |
| 110 | Even Better Than the Real Thing? Xenografting in Pediatric Patients with Scald Injury | 1.8 | 14 | Citations (PDF) |
| 111 | Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria | 4.1 | 154 | Citations (PDF) |
| 112 | Clinical presentation and outcomes of norovirus infection in intestinal allograft compared to native intestine | 2.2 | 4 | Citations (PDF) |
| 113 | Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy | 11.4 | 139 | Citations (PDF) |
| 114 | A Prolonged Outbreak of KPC-3-Producing Enterobacter cloacae and Klebsiella pneumoniae Driven by Multiple Mechanisms of Resistance Transmission at a Large Academic Burn Center | 4.1 | 80 | Citations (PDF) |
| 115 | Reply to Macesic et al | 5.2 | 0 | Citations (PDF) |
| 116 | Systems-based Practice in Burn Care | 1.8 | 8 | Citations (PDF) |
| 117 | Improving Research Enrollment of Severe Burn Patients | 0.9 | 4 | Citations (PDF) |
| 118 | The global epidemiology of carbapenemase-producing Enterobacteriaceae | 4.7 | 863 | Citations (PDF) |
| 119 | Successful Diagnosis of Intestinal Mycobacterium avium Complex Infection in a Kidney Transplant Recipient Using Nasogastric Aspirate Culture: A Case Report | 0.7 | 4 | Citations (PDF) |
| 120 | Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance | 5.2 | 335 | Citations (PDF) |
| 121 | A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae | 0.8 | 25 | Citations (PDF) |
| 122 | Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy | 0.8 | 7 | Citations (PDF) |
| 123 | Gram-Negative Bacilli in Critically Ill Burn Patients | 0.8 | 0 | Citations (PDF) |
| 124 | Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes | 2.3 | 20 | Citations (PDF) |
| 125 | Multidrug-Resistant Bacteria in the Community | 3.1 | 534 | Citations (PDF) |
| 126 | Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations | 5.2 | 536 | Citations (PDF) |
| 127 | Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis | 4.1 | 24 | Citations (PDF) |
| 128 | Predictors of persistent diarrhea in norovirus enteritis after solid organ transplantation | 1.7 | 26 | Citations (PDF) |
| 129 | Timeline of health care–associated infections and pathogens after burn injuries | 1.8 | 89 | Citations (PDF) |
| 130 | Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L | 2.7 | 20 | Citations (PDF) |
| 131 | Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258Klebsiella pneumoniaeStrains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones | 2.4 | 34 | Citations (PDF) |
| 132 | Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant Acinetobacter baumannii at a Large Academic Burn Center | 4.1 | 37 | Citations (PDF) |
| 133 | Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections | 5.3 | 111 | Citations (PDF) |
| 134 | Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae | 3.1 | 52 | Citations (PDF) |
| 135 | 456 | 0.5 | 1 | Citations (PDF) |
| 136 | Predictors of Persistent Diarrhea in Norovirus Enteritis After Solid Organ Transplantation | 0.8 | 0 | Citations (PDF) |
| 137 | Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae | 4.1 | 25 | Citations (PDF) |
| 138 | Carbapenem-Resistant Klebsiella pneumoniae Urinary Tract Infection following Solid Organ Transplantation | 4.1 | 50 | Citations (PDF) |
| 139 | Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance | 4.1 | 214 | Citations (PDF) |
| 140 | Fluoroquinolone Resistance in Escherichia coli Bloodstream Infections in Stem Cell Transplant and Hematologic Malignancy Populations | 0.8 | 0 | Citations (PDF) |
| 141 | 1804Use of Tigecycline in Patients with Carbapenem-resistant Klebsiella pneumoniae (CRKP) is Associated with Increased Risk for Readmissions with CRKP | 0.8 | 0 | Citations (PDF) |
| 142 | 368Community Origin and Mortality in Pneumonia Caused by Carbapenem-Resistant Klebsiella pneumoniae | 0.8 | 0 | Citations (PDF) |
| 143 | 895Rates and Pathogens Causing Hospital-Associated Respiratory Infections in a Regional Burn Center, 2008-2012 | 0.8 | 0 | Citations (PDF) |
| 144 | Genome Sequences of Two Carbapenemase-Resistant Klebsiella pneumoniae ST258 Isolates | 0.7 | 10 | Citations (PDF) |
| 145 | KIR and HLA Interactions Are Associated With Control of Primary CMV Infection in Solid Organ Transplant Recipients | 4.5 | 25 | Citations (PDF) |
| 146 | Functional Polymorphisms in the Gene Encoding Macrophage Migration Inhibitory Factor Are Associated With Gram-Negative Bacteremia in Older Adults | 3.7 | 23 | Citations (PDF) |
| 147 | Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections | 2.1 | 68 | Citations (PDF) |
| 148 | Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network | 4.1 | 157 | Citations (PDF) |
| 149 | The impact of multidrug resistance on outcomes in ventilator-associated pneumonia | 1.8 | 27 | Citations (PDF) |
| 150 | Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance | 5.3 | 67 | Citations (PDF) |
| 151 | Carbapenem-Resistant Klebsiella Pneumoniae Osteomyelitis and Soft Tissue Infections: A Descriptive Case Series | 0.2 | 1 | Citations (PDF) |
| 152 | Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes | 1.6 | 325 | Citations (PDF) |
| 153 | Whipple’s Disease | 0.2 | 4 | Citations (PDF) |
| 154 | OqxAB, a Quinolone and Olaquindox Efflux Pump, Is Widely Distributed among Multidrug-Resistant Klebsiella pneumoniae Isolates of Human Origin | 4.1 | 63 | Citations (PDF) |
| 155 | Vaccines, 6th Edition | 5.2 | 0 | Citations (PDF) |
| 156 | Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients | 1.3 | 159 | Citations (PDF) |
| 157 | A Dedicated Neurological Infectious Disease Consult Service: One Year of Experience (P04.016) | 1.0 | 0 | Citations (PDF) |
| 158 | Endovascular Infections Caused by Histoplasma capsulatum: A Case Series and Review of the Literature | 2.4 | 23 | Citations (PDF) |
| 159 | Diagnostic Challenges and Opportunities in Older Adults With Infectious Diseases | 5.2 | 88 | Citations (PDF) |
| 160 | Staphylococcus Aureus Bacteremia in Solid Organ Transplant Recipients | 2.1 | 50 | Citations (PDF) |
| 161 | Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms | 4.1 | 174 | Citations (PDF) |
| 162 | Increased Rate of Spontaneous Bacterial Peritonitis Among Cirrhotic Patients Receiving Pharmacologic Acid Suppression | 6.0 | 94 | Citations (PDF) |
| 163 | Challenges of Interferon-γ Release Assay Conversions in Serial Testing of Health-care Workers in a TB Control Program | 1.0 | 87 | Citations (PDF) |
| 164 | Clinical Presentation and Management of Histoplasmosis in Older Adults | 2.9 | 16 | Citations (PDF) |
| 165 | Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections | 1.6 | 155 | Citations (PDF) |
| 166 | 133 The Impact of Vaccination on Allosensitization in Candidates on the Lung Transplant Wait List | 1.1 | 0 | Citations (PDF) |
| 167 | Effect of the influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FE
NO
) and other volatiles in exhaled breath | 2.9 | 44 | Citations (PDF) |
| 168 | Extreme alkaline phosphatase elevation associated with tigecycline | 3.1 | 4 | Citations (PDF) |
| 169 | Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy | 3.8 | 22 | Citations (PDF) |
| 170 | Recommended curriculum for subspecialty training in transplant infectious disease on behalf of the American Society of Transplantation Infectious Diseases Community of Practice Educational Initiatives Working Group | 2.2 | 18 | Citations (PDF) |
| 171 | Reply to Hage et al | 5.2 | 1 | Citations (PDF) |
| 172 | Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection | 1.6 | 20 | Citations (PDF) |
| 173 | Histoplasmosis in Solid Organ Transplant Recipients: 10 Years of Experience at a Large Transplant Center in an Endemic Area | 5.2 | 212 | Citations (PDF) |
| 174 | 538: MICA Gene Polymorphisms and Primary CMV Infection in the CMV D+/R- Thoracic Organ Transplants | 1.1 | 0 | Citations (PDF) |
| 175 | Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults | 3.7 | 161 | Citations (PDF) |
| 176 | Toll‐Like Receptors in Older Adults | 2.9 | 119 | Citations (PDF) |
| 177 | Triggering TLR signaling in vaccination | 10.4 | 342 | Citations (PDF) |
| 178 | Blastomyces dermatitidis produces melanin in vitro and during infection | 1.9 | 44 | Citations (PDF) |
| 179 | Effects of Voriconazole on
Cryptococcus neoformans | 4.1 | 75 | Citations (PDF) |
| 180 | Melanization of
Cryptococcus neoformans
and
Histoplasma capsulatum
Reduces Their Susceptibilities to Amphotericin B and Caspofungin | 4.1 | 213 | Citations (PDF) |
| 181 | Seizures in the Critically Ill: The Role of Imipenem | 4.4 | 54 | Citations (PDF) |
| 182 | The BioWipe: a non-invasive method to detect intestinal carriage of multi-drug resistant GRAM-negative bacteria | 1.5 | 1 | Citations (PDF) |
| 183 | The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must Follow | 5.2 | 0 | Citations (PDF) |
| 184 | What Is Antimicrobial Resistance? | 16.5 | 0 | Citations (PDF) |
| 185 | Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset | 0.8 | 0 | Citations (PDF) |
| 186 | Impact of eravacycline on fibrinogen | 3.1 | 1 | Citations (PDF) |
| 187 | P-1292. Clinical and Genomic Features of Colistin Resistance Among Carbapenem-resistant Acinetobacter baumannii Isolated From Global Clinical Samples | 0.8 | 0 | Citations (PDF) |
| 188 | P-1856. Desirability of Outcome Ranking Analysis Framework for Patients on Outpatient Parenteral Antimicrobial Therapy: A Proof-of-Concept Study in Immunocompromised Patients Receiving Daptomycin or Vancomycin | 0.8 | 0 | Citations (PDF) |
| 189 | P-2068. Area Deprivation Is Linked to Prevalence of Multidrug Resistance in Enterobacterales Clinical Isolates | 0.8 | 0 | Citations (PDF) |
| 190 | Development of a Kidney Transplant‐Specific DOOR for Urinary Tract Infections Assessing the Impact of Carbapenem Resistance | 2.2 | 0 | Citations (PDF) |
| 191 | A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol | 4.4 | 0 | Citations (PDF) |
| 192 | Sulbactam–durlobactam and cefiderocol combination treatment of
Burkholderia cenocepacia
-associated Fitz–Hugh–Curtis syndrome | 4.1 | 1 | Citations (PDF) |
| 193 | Rate of and Risk Factors for 30-Day All-Cause Hospital Readmission in Solid Organ Transplant Patients Receiving Outpatient Parenteral Antimicrobial Therapy | 4.5 | 0 | Citations (PDF) |
